The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.
Study Type
OBSERVATIONAL
Enrollment
1,830
Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
Unnamed facility
Wiesloch, Baden-Wurttemberg, Germany
Intraocular Pressure (IOP) in the Study Eye at Baseline
IOP is a measurement of the fluid pressure inside the study eye.
Time frame: Baseline
IOP in the Study Eye at Week 12
IOP is a measurement of the fluid pressure inside the study eye.
Time frame: Week 12
Physician Assessment of IOP-Lowering Effect in the Study Eye on a 3-Point Scale
IOP is a measurement of the fluid pressure inside the eye. Physicians evaluate IOP change from baseline in the study eye as better than expected, as expected, and worse than expected. The numbers of patients in each category are presented.
Time frame: Baseline, 12 Weeks
Patient Assessment of Tolerability on a 4-Point Scale
Patient assessment of tolerability is assessed using a 4-point scale (very good, good, moderate, and poor). The numbers of patients in each category are presented.
Time frame: 12 Weeks
Physician Assessment of Tolerability on a 4-Point Scale
Physician assessment of tolerability is assessed using a 4-point scale (very good, good, moderate, and poor). The numbers of patients in each category are presented.
Time frame: 12 Weeks
Number of Patients Who Discontinue Treatment With Lumigan® UD Prior to 12 Weeks of Treatment
Patient discontinuation of treatment with Lumigan® UD prior to 12 weeks of treatment is assessed as Yes or No.
Time frame: 12 Weeks
Number of Patients Who Continue Treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patient continuation of treatment with Lumigan® UD after the end of study participation is assessed as Yes or No.
Time frame: 12 Weeks
Physician Assessment of Patient Compliance Compared to Previous Treatment on a 3-Point Scale
Physician assessment of patient compliance compared to previous therapy is assessed on a 3-point scale (better, equal, and worse). The numbers of patients in each category are presented.
Time frame: 12 Weeks